164 related articles for article (PubMed ID: 28825695)
1. Augmenter of liver regeneration potentiates doxorubicin anticancer efficacy by reducing the expression of ABCB1 and ABCG2 in hepatocellular carcinoma.
Guo YY; Wu Y; Jia XW; An W
Lab Invest; 2017 Dec; 97(12):1400-1411. PubMed ID: 28825695
[TBL] [Abstract][Full Text] [Related]
2. Liver regeneration associated protein (ALR) exhibits antimetastatic potential in hepatocellular carcinoma.
Dayoub R; Wagner H; Bataille F; Stöltzing O; Spruss T; Buechler C; Schlitt HJ; Weiss TS
Mol Med; 2011; 17(3-4):221-8. PubMed ID: 21152698
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells.
Yin W; Xiang D; Wang T; Zhang Y; Pham CV; Zhou S; Jiang G; Hou Y; Zhu Y; Han Y; Qiao L; Tran PH; Duan W
Sci Rep; 2021 May; 11(1):10791. PubMed ID: 34031441
[TBL] [Abstract][Full Text] [Related]
4. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
5. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
[TBL] [Abstract][Full Text] [Related]
6. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.
Hou H; Sun H; Lu P; Ge C; Zhang L; Li H; Zhao F; Tian H; Zhang L; Chen T; Yao M; Li J
Mol Cancer Ther; 2013 Dec; 12(12):2874-84. PubMed ID: 24130050
[TBL] [Abstract][Full Text] [Related]
7. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
8. C-terminal truncated HBx reduces doxorubicin cytotoxicity via ABCB1 upregulation in Huh-7 hepatocellular carcinoma cells.
Jegal ME; Jung SY; Han YS; Kim YJ
BMB Rep; 2019 May; 52(5):330-335. PubMed ID: 30982500
[TBL] [Abstract][Full Text] [Related]
9. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
10. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo.
Chen Z; Chen Y; Xu M; Chen L; Zhang X; To KK; Zhao H; Wang F; Xia Z; Chen X; Fu L
Mol Cancer Ther; 2016 Aug; 15(8):1845-58. PubMed ID: 27196753
[TBL] [Abstract][Full Text] [Related]
12. Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function.
Robinson AN; Tebase BG; Francone SC; Huff LM; Kozlowski H; Cossari D; Lee JM; Esposito D; Robey RW; Gottesman MM
Drug Metab Dispos; 2019 Jul; 47(7):715-723. PubMed ID: 31048454
[TBL] [Abstract][Full Text] [Related]
13. Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma.
Sukowati CH; Rosso N; Pascut D; Anfuso B; Torre G; Francalanci P; Crocè LS; Tiribelli C
BMC Gastroenterol; 2012 Nov; 12():160. PubMed ID: 23153066
[TBL] [Abstract][Full Text] [Related]
14. Expression of augmenter of liver regeneration (ALR) in human liver cirrhosis and carcinoma.
Thasler WE; Schlott T; Thelen P; Hellerbrand C; Bataille F; Lichtenauer M; Schlitt HJ; Jauch KW; Weiss TS
Histopathology; 2005 Jul; 47(1):57-66. PubMed ID: 15982324
[TBL] [Abstract][Full Text] [Related]
15. Liver-specific deletion of augmenter of liver regeneration accelerates development of steatohepatitis and hepatocellular carcinoma in mice.
Gandhi CR; Chaillet JR; Nalesnik MA; Kumar S; Dangi A; Demetris AJ; Ferrell R; Wu T; Divanovic S; Stankeiwicz T; Shaffer B; Stolz DB; Harvey SA; Wang J; Starzl TE
Gastroenterology; 2015 Feb; 148(2):379-391.e4. PubMed ID: 25448926
[TBL] [Abstract][Full Text] [Related]
16. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
18. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
19. Imbalance in ALR ubiquitination accelerates the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma.
Zheng M; Ai Z; Guo Y; Chen Y; Xie P; An W
Oncogene; 2023 Jan; 42(4):308-321. PubMed ID: 36434180
[TBL] [Abstract][Full Text] [Related]
20. Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells.
Karaosmanoğlu O; Banerjee S; Sivas H
Cell Oncol (Dordr); 2018 Aug; 41(4):439-453. PubMed ID: 29858962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
